1 3614 121 IN VITRO CELL TRANSFORMATION ASSAYS: A VALUABLE APPROACH FOR CARCINOGENIC POTENTIALITY ASSESSMENT OF NANOMATERIALS. THIS REVIEW EXPLORES THE APPLICATION OF IN VITRO CELL TRANSFORMATION ASSAYS (CTAS) AS A SCREENING PLATFORM TO ASSESS THE CARCINOGENIC POTENTIAL OF NANOMATERIALS (NMS) RESULTING FROM CONTINUOUSLY GROWING INDUSTRIAL PRODUCTION AND USE. THE WIDESPREAD APPLICATION OF NMS IN VARIOUS FIELDS HAS RAISED CONCERNS ABOUT THEIR POTENTIAL ADVERSE EFFECTS, NECESSITATING SAFETY EVALUATIONS, PARTICULARLY IN LONG-TERM CONTINUOUS EXPOSURE SCENARIOS. CTAS PRESENT A REALISTIC SCREENING PLATFORM FOR KNOWN AND EMERGING NMS BY EXAMINING THEIR RESEMBLANCE TO THE HALLMARK OF MALIGNANCY, INCLUDING HIGH PROLIFERATION RATES, LOSS OF CONTACT INHIBITION, THE GAIN OF ANCHORAGE-INDEPENDENT GROWTH, CELLULAR INVASION, DYSREGULATION OF THE CELL CYCLE, APOPTOSIS RESISTANCE, AND ABILITY TO FORM TUMORS IN EXPERIMENTAL ANIMALS. THROUGH THE DELIBERATE TRANSFORMATION OF CELLS VIA CHRONIC NM EXPOSURE, RESEARCHERS CAN INVESTIGATE THE TUMORIGENIC PROPERTIES OF NMS AND THE UNDERLYING MECHANISMS OF CANCER DEVELOPMENT. THIS ARTICLE EXAMINES NM-INDUCED CELL TRANSFORMATION STUDIES, FOCUSING ON IDENTIFYING EXISTING KNOWLEDGE GAPS. SPECIFICALLY, IT EXPLORES THE PHYSICOCHEMICAL PROPERTIES OF NMS, EXPERIMENTAL MODELS, ASSAYS, DOSE AND TIME REQUIREMENTS FOR CELL TRANSFORMATION, AND THE UNDERLYING MECHANISMS OF MALIGNANCY. OUR REVIEW AIMS TO ADVANCE UNDERSTANDING IN THIS FIELD AND IDENTIFY AREAS FOR FURTHER INVESTIGATION. 2023 2 429 20 ANTI-INFLAMMATORY TOPICAL MEDICATION - NEW DEVELOPMENTS IN THE TREATMENT OF ATOPIC DERMATITIS. ATOPIC DERMATITIS IS A CHRONIC INFLAMMATORY DISEASE THAT ARISES FROM POLYGENIC DISPOSITION, A DYSFUNCTION OF THE PHYSICOCHEMICAL EPITHELIAL BARRIER, A CUTANEOUS DYSBIOSIS, AND A FAULTY NEUROSENSORY ACTIVITY AND SHOWS A HIGHLY INDIVIDUAL ACUITY DUE TO EPIGENETIC FACTORS. AN ESSENTIAL COMPONENT OF THERAPEUTIC MANAGEMENT IS THE APPLICATION OF ANTI-INFLAMMATORY TOPICAL MEDICATION. CURRENTLY, TOPICAL GLUCOCORTICOIDS AND TOPICAL CALCINEURIN INHIBITORS ARE ROUTINELY USED IN REACTIVE AND PROACTIVE THERAPY. IN RECENT YEARS, THE DEVELOPMENT OF MOLECULAR MEDICINE HAS IDENTIFIED SEVERAL NEW THERAPEUTIC TARGETS THAT HAVE ENABLED THE DEVELOPMENT OF INNOVATIVE THERAPEUTIC APPROACHES. IN ADDITION TO PHOSPHODIESTERASE-4 INHIBITORS AND ARYL HYDROCARBON RECEPTOR MODULATORS, IT IS MAINLY JANUS KINASE INHIBITORS WITH DIFFERENT SELECTIVITY THAT ARE EMERGING AS NEW EFFECTIVE AND SAFE OPTIONS FOR TOPICAL THERAPY. THE CURRENT DATA SUGGESTS THAT IN THE COMING MONTHS AND YEARS REPRESENTATIVES OF THE ABOVE-MENTIONED SUBSTANCE CLASSES WILL BE APPROVED FOR TOPICAL USE. 2021 3 3074 23 GENOME-WIDE DNA METHYLOME AND TRANSCRIPTOME CHANGES INDUCED BY INORGANIC NANOPARTICLES IN HUMAN KIDNEY CELLS AFTER CHRONIC EXPOSURE. THE UNIQUE PHYSICOCHEMICAL PROPERTIES MAKE INORGANIC NANOPARTICLES (INPS) AN EXCITING TOOL IN DIAGNOSIS AND DISEASE MANAGEMENT. HOWEVER, AS INPS ARE RELATIVELY DIFFICULT TO FULLY DEGRADE AND EXCRETE, THEIR UNINTENDED ACCUMULATION IN THE TISSUE MIGHT RESULT IN ADVERSE HEALTH EFFECTS. HEREIN, WE PROVIDE A METHYLOME-TRANSCRIPTOME FRAMEWORK FOR CHRONIC EFFECTS OF INPS, COMMONLY USED IN BIOMEDICAL APPLICATIONS, IN HUMAN KIDNEY TH-1 CELLS. RENAL CLEARANCE IS ONE OF THE MOST IMPORTANT ROUTES OF NANOPARTICLE EXCRETION; THEREFORE, A DETAILED EVALUATION OF NANOPARTICLE-MEDIATED NEPHROTOXICITY IS AN IMPORTANT TASK. INTEGRATED ANALYSIS OF METHYLOME AND TRANSCRIPTOME CHANGES INDUCED BY INPS (PEG-AUNPS, FE(3)O(4)NPS, SIO(2)NPS, AND TIO(2)NPS) REVEALED SIGNIFICANTLY DEREGULATED GENES WITH FUNCTIONAL CLASSIFICATION IN IMMUNE RESPONSE, DNA DAMAGE, AND CANCER-RELATED PATHWAYS. ALTHOUGH MOST DEREGULATED GENES WERE UNIQUE TO INDIVIDUAL INPS, A RELATIVELY HIGH PROPORTION OF THEM ENCODED THE TRANSCRIPTION FACTORS. INTERESTINGLY, FOS HYPERMETHYLATION INVERSELY CORRELATING WITH GENE EXPRESSION WAS ASSOCIATED WITH ALL INPS EXPOSURES. OUR STUDY EMPHASIZES THE NEED FOR A MORE COMPREHENSIVE INVESTIGATION OF INPS' BIOLOGICAL SAFETY, ESPECIALLY AFTER CHRONIC EXPOSURE. 2022 4 4312 36 MICRORNAS AS A SUITABLE BIOMARKER TO DETECT THE EFFECTS OF LONG-TERM EXPOSURES TO NANOMATERIALS. STUDIES ON TIO(2)NP AND MWCNT. THE PRESENCE OF NANOMATERIALS (NMS) IN THE ENVIRONMENT MAY REPRESENT A SERIOUS RISK TO HUMAN HEALTH, ESPECIALLY IN A SCENARIO OF CHRONIC EXPOSURE. TO EVALUATE THE POTENTIAL RELATIONSHIP BETWEEN NM-INDUCED EPIGENETIC ALTERATIONS AND CARCINOGENESIS, THE PRESENT STUDY ANALYZED A PANEL OF 33 MIRNAS RELATED TO THE CELL TRANSFORMATION PROCESS IN BEAS-2B CELLS TRANSFORMED BY TIO(2)NP AND LONG-TERM MWCNT EXPOSURE. OUR BATTERY REVEALED A LARGE IMPACT ON MIRNA EXPRESSION PROFILING IN CELLS EXPOSED TO BOTH NMS. FROM THIS ANALYSIS, A SMALL SET OF FIVE MIRNAS (MIR-23A, MIR-25, MIR-96, MIR-210, AND MIR-502) WERE IDENTIFIED AS INFORMATIVE BIOMARKERS OF THE TRANSFORMING EFFECTS INDUCED BY NM EXPOSURES. THE USEFULNESS OF THIS REDUCED MIRNA BATTERY WAS FURTHER VALIDATED IN OTHER PREVIOUSLY GENERATED TRANSFORMED CELL SYSTEMS BY LONG-TERM EXPOSURE TO OTHER NMS (CONP, ZNONP, MSINP, AND CEO(2)NP). INTERESTINGLY, THE FIVE SELECTED MIRNAS WERE CONSISTENTLY OVEREXPRESSED IN ALL CELL LINES AND NMS TESTED. THESE RESULTS CONFIRM THE SUITABILITY OF THE PROPOSED SET OF MRNAS TO IDENTIFY THE POTENTIAL TRANSFORMING ABILITY OF NMS. PARTICULAR ATTENTION SHOULD BE PAID TO THE EPIGENOME AND ESPECIALLY TO MIRNAS FOR HAZARD ASSESSMENT OF NMS, AS WELLS AS FOR THE STUDY OF THE UNDERLYING MECHANISMS OF ACTION. 2021 5 4588 42 NANOPARTICLE EXPOSURES FROM NANO-ENABLED TONER-BASED PRINTING EQUIPMENT AND HUMAN HEALTH: STATE OF SCIENCE AND FUTURE RESEARCH NEEDS. TONER FORMULATIONS USED BY LASER PRINTERS (LP) AND PHOTOCOPIERS (PC), COLLECTIVELY CALLED "TONER-BASED PRINTING EQUIPMENT" (TPE), ARE NANO-ENABLED PRODUCTS (NEP) BECAUSE THEY CONTAIN SEVERAL ENGINEERED NANOMATERIALS (ENM) THAT IMPROVE TONER PERFORMANCE. IT HAS BEEN SHOWN THAT DURING CONSUMER USE (PRINTING), THESE ENM ARE RELEASED IN THE AIR, TOGETHER WITH OTHER SEMI-VOLATILE ORGANIC NANOPARTICLES, AND NEWLY FORMED GASEOUS CO-POLLUTANTS SUCH AS VOLATILE ORGANIC COMPOUNDS (VOC). THE AIM OF THIS REVIEW IS TO DETAIL AND ANALYZE PHYSICO-CHEMICAL AND MORPHOLOGICAL (PCM), AS WELL AS THE TOXICOLOGICAL PROPERTIES OF PARTICULATE MATTER (PM) EMISSIONS FROM TPE. THE REVIEW COVERS EVOLUTION OF SCIENCE SINCE THE EARLY 2000, WHEN THIS PRINTING TECHNOLOGY FIRST BECAME A SUBJECT OF PUBLIC INTEREST, AS WELL AS THE LAGGING REGULATORY FRAMEWORK AROUND IT. IMPORTANT STUDIES THAT HAVE SIGNIFICANTLY CHANGED OUR UNDERSTANDING OF THESE EXPOSURES ARE ALSO HIGHLIGHTED. THE REVIEW CONTINUES WITH A CRITICAL APPRAISAL OF THE MOST UP-TO-DATE CELLULAR, ANIMAL AND HUMAN TOXICOLOGICAL EVIDENCE ON THE POTENTIAL ADVERSE HUMAN HEALTH EFFECTS OF PM EMITTED FROM TPE. WE HIGHLIGHT SEVERAL LIMITATIONS OF EXISTING STUDIES, INCLUDING (I) USE OF HIGH AND OFTEN UNREALISTIC DOSES IN VITRO OR IN VIVO; (II) UNREALISTICALLY HIGH-DOSE RATES IN INTRATRACHEAL INSTILLATION STUDIES; (III) IMPROPER USE OF TONERS AS SURROGATE FOR EMITTED NANOPARTICLES; (IV) LACK OF OR INADEQUATE PCM CHARACTERIZATION OF EXPOSURES; AND (V) LACK OF DOSIMETRY CONSIDERATIONS IN IN VITRO STUDIES. PRESENTLY, THERE IS COMPELLING EVIDENCE THAT THE PM(0.1) FROM TPE ARE BIOLOGICALLY ACTIVE AND CAPABLE OF INDUCING OXIDATIVE STRESS IN VITRO AND IN VIVO, RESPIRATORY TRACT INFLAMMATION IN VIVO (IN RATS) AND IN HUMANS, SEVERAL ENDPOINTS OF CELLULAR INJURY IN MONOCULTURES AND CO-CULTURES, INCLUDING MODERATE EPIGENETIC MODIFICATIONS IN VITRO. IN HUMANS, LIMITED EPIDEMIOLOGICAL STUDIES REPORT TYPICALLY 2-3 TIMES HIGHER PREVALENCE OF CHRONIC COUGH, WHEEZING, NASAL BLOCKAGE, EXCESSIVE SPUTUM PRODUCTION, BREATHING DIFFICULTIES, AND SHORTNESS OF BREATH, IN COPIER OPERATORS RELATIVE TO CONTROLS. SUCH SYMPTOMS CAN BE EXACERBATED DURING CHRONIC EXPOSURES, AND IN INDIVIDUALS SUSCEPTIBLE TO INHALED POLLUTANTS. THUS RESPIRATORY, IMMUNOLOGICAL, CARDIOVASCULAR, AND OTHER DISORDERS MAY BE DEVELOPED FOLLOWING SUCH EXPOSURES; HOWEVER, FURTHER TOXICOLOGICAL AND LARGER SCALE MOLECULAR EPIDEMIOLOGICAL STUDIES MUST BE DONE TO FULLY UNDERSTAND THE MECHANISM OF ACTION OF THESE TPE EMITTED NANOPARTICLES. MAJOR RESEARCH GAPS HAVE ALSO BEEN IDENTIFIED. AMONG THEM, A METHODICAL RISK ASSESSMENT BASED ON "REAL WORLD" EXPOSURES RATHER THAN ON THE TONER PARTICLES ALONE NEEDS TO BE PERFORMED TO PROVIDE THE MUCH-NEEDED DATA TO ESTABLISH REGULATORY GUIDELINES PROTECTIVE OF INDIVIDUALS EXPOSED TO TPE EMISSIONS AT BOTH THE OCCUPATIONAL AND CONSUMER LEVEL. INDUSTRY-WIDE MOLECULAR EPIDEMIOLOGY AS WELL AS MECHANISTIC ANIMAL AND HUMAN STUDIES ARE ALSO URGENTLY NEEDED. 2017 6 1943 27 EPIDERMAL GROWTH FACTOR IN HEALING DIABETIC FOOT ULCERS: FROM GENE EXPRESSION TO TISSUE HEALING AND SYSTEMIC BIOMARKER CIRCULATION. LOWER-EXTREMITY DIABETIC ULCERS ARE RESPONSIBLE FOR 80% OF ANNUAL WORLDWIDE NONTRAUMATIC AMPUTATIONS. EPIDERMAL GROWTH FACTOR (EGF) REDUCTION IS ONE OF THE MOLECULAR PILLARS OF DIABETIC ULCER CHRONICITY, THUS EGF ADMINISTRATION MAY BE CONSIDERED A TYPE OF REPLACEMENT THERAPY. TOPICAL EGF AD-MINISTRATION TO IMPROVE AND SPEED WOUND HEALING BEGAN IN 1989 ON BURN PATIENTS AS PART OF AN ACUTE-HEALING THERAPY. FURTHER CLINICAL STUDIES BASED ON TOPICALLY ADMINISTERING EGF TO DIFFERENT CHRONIC WOUNDS RESULTED IN DISAPPOINTING OUT-COMES. AN ANALYSIS OF THE LITERATURE ON UNSUCCESSFUL CLINICAL TRIALS IDENTIFI ED A LACK OF KNOWLEDGE CONCERNING: (I) MOLECULAR AND CELLULAR FOUNDATIONS OF WOUND CHRONICITY AND (II) THE PHAR-MACODYNAMIC REQUISITES GOVERNING EGF INTERACTION WITH ITS RECEPTOR TO PROMOTE CELL RESPONSE. YET, EGF INTRA- AND PERILE-SIONAL INFI LTRATION WERE SHOWN TO CIRCUMVENT THE PHARMACODY-NAMIC LIMITATIONS OF TOPICAL APPLICATION. SINCE THE FI RST STUDIES, THE FOLLOWING DECADES OF BASIC AND CLINICAL RESEARCH ON EGF THERAPY FOR PROBLEM WOUNDS HAVE SHED LIGHT ON POTENTIAL USES OF GROWTH FACTORS IN REGENERATIVE MEDICINE. EGF'S MOLECULAR AND BIOCHEMICAL EFFECTS AT BOTH LOCAL AND SYSTEMIC LEVELS ARE DIVERSE: (1) DOWNREGULATION OF GENES ENCODING INFL AMMATION MEDIATORS AND INCREASED EXPRESSION OF GENES INVOLVED IN CELL PROLIFERATION, ANGIOGENESIS AND MATRIX SECRETION; (2) EGF IN-TERVENTION POSITIVELY IMPACTS BOTH MESENCHYMAL AND EPITHELIAL CELLS, REDUCING INFL AMMATION AND STIMULATING THE RECRUITMENT OF PRECURSOR CIRCULATING CELLS THAT PROMOTE THE FORMATION OF NEW BLOOD VESSELS; (3) AT THE SUBCELLULAR LEVEL, UPREGULATION OF THE EGF RECEPTOR WITH SUBSEQUENT INTRACELLULAR TRAFFI CKING, INCLUD-ING MITOCHONDRIAL ALLOCATION ALONG WITH RESTORED MORPHOLOGY OF MULTIPLE ORGANELLES; AND (4) LOCAL EGF INFI LTRATION RESULTING IN A SYSTEMIC, ORGANISMAL REPERCUSSION, THUS CONTRIBUTING TO ATTENUATION OF CIRCULATING INFL AMMATORY AND CATABOLIC REAC-TANTS, RESTORED REDUCTION-OXIDATION BALANCE, AND DECREASED TOXIC GLYCATION PRODUCTS AND SOLUBLE APOPTOGENIC EFFECTORS. IT IS LIKELY THAT EGF TREATMENT MAY REARRANGE CRITICAL EPIGENETIC DRIVERS OF DIABETIC METABOLIC MEMORY. KEYWORDS EPIDERMAL GROWTH FACTOR, DIABETES, DIABETES COMPLICATIONS, WOUND HEALING, DIABETIC FOOT, AMPUTATION, ULCER, CUBA. 2020 7 5797 27 STEM CELL-BASED THERAPY FOR HIRSCHSPRUNG DISEASE, DO WE HAVE THE GUTS TO TREAT? HIRSCHSPRUNG DISEASE (HSCR) IS A CONGENITAL ANOMALY OF THE COLON THAT RESULTS FROM FAILURE OF ENTERIC NERVOUS SYSTEM FORMATION, LEADING TO A CONSTRICTED DYSFUNCTIONAL SEGMENT OF THE COLON WITH VARIABLE LENGTHS, AND NECESSITATING SURGICAL INTERVENTION. THE UNDERLYING PATHOPHYSIOLOGY INCLUDES A DEFECT IN NEURAL CREST CELLS MIGRATION, PROLIFERATION AND DIFFERENTIATION, WHICH ARE PARTIALLY EXPLAINED BY IDENTIFIED GENETIC AND EPIGENETIC ALTERATIONS. DESPITE THE HIGH SUCCESS RATE OF THE CURATIVE SURGERIES, THEY ARE ASSOCIATED WITH SIGNIFICANT ADVERSE OUTCOMES SUCH AS ENTEROCOLITIS, FECAL SOILING, AND CHRONIC CONSTIPATION. IN ADDITION, SOME PATIENTS SUFFER FROM EXTENSIVE LETHAL VARIANTS OF THE DISEASE, ALL OF WHICH JUSTIFY THE NEED FOR AN ALTERNATIVE CURE. DURING THE LAST 5 YEARS, THERE HAS BEEN CONSIDERABLE PROGRESS IN HSCR STEM CELL-BASED THERAPY RESEARCH. HOWEVER, MANY MAJOR ISSUES REMAIN UNSOLVED. THIS REVIEW WILL PROVIDE CONCISE BACKGROUND INFORMATION ON HSCR, OUTLINE THE FUTURE APPROACHES OF STEM CELL-BASED HSCR THERAPY, REVIEW RECENT KEY PUBLICATIONS, DISCUSS TECHNICAL AND ETHICAL CHALLENGES THE FIELD FACES PRIOR TO CLINICAL TRANSLATION, AND TACKLE SUCH CHALLENGES BY PROPOSING SOLUTIONS AND EVALUATING EXISTING APPROACHES TO PROGRESS FURTHER. 2022 8 6439 29 THERAPEUTIC ANTIBODIES: CURRENT STATE AND FUTURE TRENDS--IS A PARADIGM CHANGE COMING SOON? ANTIBODY-BASED THERAPEUTICS CURRENTLY ENJOY UNPRECEDENTED SUCCESS, GROWTH IN RESEARCH AND REVENUES, AND RECOGNITION OF THEIR POTENTIAL. IT APPEARS THAT THE PROMISE OF THE "MAGIC BULLET" HAS LARGELY BEEN REALIZED. THERE ARE CURRENTLY 22 MONOCLONAL ANTIBODIES (MABS) APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR CLINICAL USE AND HUNDREDS ARE IN CLINICAL TRIALS FOR TREATMENT OF VARIOUS DISEASES INCLUDING CANCERS, IMMUNE DISORDERS, AND INFECTIONS. THE REVENUES FROM THE TOP FIVE THERAPEUTIC ANTIBODIES (RITUXAN, REMICADE, HERCEPTIN, HUMIRA, AND AVASTIN) NEARLY DOUBLED FROM $6.4 BILLION IN 2004 TO $11.7 BILLION IN 2006. DURING THE LAST SEVERAL YEARS MAJOR PHARMACEUTICAL COMPANIES RACED TO ACQUIRE ANTIBODY COMPANIES, WITH A RECENT EXAMPLE OF MEDIMMUNE BEING PURCHASED FOR $15.6 BILLION BY ASTRAZENECA. THESE THERAPEUTIC AND BUSINESS SUCCESSES REFLECT THE MAJOR ADVANCES IN ANTIBODY ENGINEERING WHICH HAVE RESULTED IN THE GENERATION OF SAFE, SPECIFIC, HIGH-AFFINITY, AND NON-IMMUNOGENIC ANTIBODIES DURING THE LAST THREE DECADES. CURRENTLY, SECOND AND THIRD GENERATIONS OF ANTIBODIES ARE UNDER DEVELOPMENT, MOSTLY TO IMPROVE ALREADY EXISTING ANTIBODY SPECIFICITIES. HOWEVER, ALTHOUGH THE REFINEMENT OF ALREADY KNOWN METHODOLOGIES IS CERTAINLY OF GREAT IMPORTANCE FOR POTENTIAL CLINICAL USE, THERE ARE NO CONCEPTUALLY NEW DEVELOPMENTS IN THE LAST DECADE COMPARABLE, FOR EXAMPLE, TO THE DEVELOPMENT OF ANTIBODY LIBRARIES, PHAGE DISPLAY, DOMAIN ANTIBODIES (DABS), AND ANTIBODY HUMANIZATION TO NAME A FEW. A FUNDAMENTAL QUESTION IS THEN WHETHER THERE WILL BE ANOTHER CHANGE IN THE PARADIGM OF RESEARCH AS HAPPENED 1-2 DECADES AGO OR THE CURRENT TREND OF GRADUAL IMPROVEMENT OF ALREADY DEVELOPED METHODOLOGIES AND THERAPEUTIC ANTIBODIES WILL CONTINUE. ALTHOUGH ANY PREDICTION COULD PROVE INCORRECT, IT APPEARS THAT CONCEPTUALLY NEW METHODOLOGIES ARE NEEDED TO OVERCOME THE FUNDAMENTAL PROBLEMS OF DRUG (ANTIBODY) RESISTANCE DUE TO GENETIC OR/AND EPIGENETIC ALTERATIONS IN CANCER AND CHRONIC INFECTIONS, AS WELL AS PROBLEMS RELATED TO ACCESS TO TARGETS AND COMPLEXITY OF BIOLOGICAL SYSTEMS. IF NEW METHODOLOGIES ARE NOT DEVELOPED, IT IS LIKELY THAT GRADUAL SATURATION WILL OCCUR IN THE PIPELINE OF CONCEPTUALLY NEW ANTIBODY THERAPEUTICS. IN THIS SCENARIO WE WILL WITNESS AN INCREASE IN COMBINATION OF TARGETS AND ANTIBODIES, AND FURTHER ATTEMPTS TO PERSONALIZE TARGETED TREATMENTS BY USING APPROPRIATE BIOMARKERS AS WELL AS TO DEVELOP NOVEL SCAFFOLDS WITH PROPERTIES THAT ARE SUPERIOR TO THOSE OF THE ANTIBODIES NOW IN CLINICAL USE. 2009 9 5087 22 PIMECROLIMUS FOR THE TREATMENT OF ATOPIC DERMATITIS IN INFANTS: AN ASIAN PERSPECTIVE. ATOPIC DERMATITIS (AD) IS A COMMON CHRONIC, MULTISYSTEM INFLAMMATORY SKIN DISEASE IN PEDIATRIC PATIENTS. THERE HAS BEEN AN INCREASE IN THE INCIDENCE OF AD IN THE PEDIATRIC POPULATION OF THE ASIA-PACIFIC REGION. STUDIES HAVE SHOWN THAT GENETIC, EPIGENETIC, ENVIRONMENTAL AND CULTURAL FACTORS MAY LEAD TO DIFFERENCES IN THE CLINICAL MANIFESTATION AND PREVALENCE OF AD BETWEEN RACES. EARLY TREATMENT OF AD IS NECESSARY TO PREVENT THE ATOPIC MARCH LEADING TO COMORBIDITIES SUCH AS ASTHMA AND ALLERGIC RHINITIS. TOPICAL CORTICOSTEROIDS (TCS) ARE USED AS FIRST-LINE THERAPY FOR THE TREATMENT OF AD, BUT THEIR LONG-TERM USAGE POSES A RISK TO THE PATIENT'S HEALTH. PIMECROLIMUS (1%) IS A TOPICAL CALCINEURIN INHIBITOR (TCI) THAT IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE AD. PIMECROLIMUS HAS NO APPARENT INCREASE IN ADVERSE EVENTS COMPARED TO TCS, AND IT CAUSES LESS OF A BURNING SENSATION THAN TACROLIMUS. THE SAFETY AND EFFICACY OF PIMECROLIMUS HAS BEEN ESTABLISHED THROUGH VARIOUS CLINICAL TRIALS; YET, IN MANY ASIAN COUNTRIES, THE USE OF PIMECROLIMUS IN INFANTS IS STILL RESTRICTED DUE TO SAFETY CONCERNS. BASED ON THE AVAILABLE EVIDENCE, THE EXPERT PANEL RECOMMENDS PIMECROLIMUS IN INFANTS BETWEEN 3 MONTHS AND 2 YEARS OF AGE IN THE ASIAN POPULATION. 2023 10 3485 27 IDENTIFICATION OF CIRCULAR RNAS EXPRESSION PATTERN IN CAPRINE FETAL FIBROBLAST CELLS EXPOSED TO A CHRONIC NON-CYTOTOXIC DOSE OF GRAPHENE OXIDE-SILVER NANOPARTICLE NANOCOMPOSITES. THE WIDESPREAD USE OF GRAPHENE OXIDE-SILVER NANOPARTICLE NANOCOMPOSITES (GO-AGNPS) IN BIOMEDICAL SCIENCES IS INCREASING THE CHANCES OF HUMAN AND ANIMAL EXPOSURE TO ITS CHRONIC NON-TOXIC DOSES. EXPOSURE TO AGNPS-RELATED NANOMATERIALS MAY RESULT IN THE NEGATIVE EFFECT ON THE DAM, FETUS AND OFFSPRING. HOWEVER, THERE ARE ONLY LITTLE AVAILABLE INFORMATION FOR PROFOUND UNDERSTANDING OF THE EPIGENETIC ALTERATION IN THE CELLS AND ANIMALS CAUSED BY LOW-DOSE CHRONIC EXPOSURE OF GO-AGNPS. THE PRESENT STUDY INVESTIGATED THE EFFECT OF 0.5 MUG/ML GO-AGNPS FOR 10 WEEKS ON THE DIFFERENTIAL EXPRESSION OF CIRCULAR RNAS (CIRCRNAS) IN CAPRINE FETAL FIBROBLAST CELLS (CFFCS), AND THIS DOSE OF GO-AGNPS DID NOT AFFECT CELL VIABILITY AND ROS LEVEL. WE PREDICTED THE FUNCTIONS OF THOSE DIFFERENTIALLY EXPRESSED (DE) CIRCRNAS IN CFFCS BY BIOINFORMATICS ANALYSIS. FURTHERMORE, WE VALIDATED THE EXPRESSION OF TEN DE CIRCRNAS USING QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (QRT-PCR) TO ENSURE THE RELIABILITY OF THE SEQUENCING DATA. OUR RESULTS SHOWED THAT THE DE CIRCRNAS MAY POTENTIALLY REGULATE THE GO-AGNPS-INDUCING EPIGENETIC TOXICITY THROUGH A REGULATORY NETWORK CONSISTED OF CIRCRNAS, MIRNAS AND MESSENGER RNAS (MRNAS). THEREFORE, THE EPIGENETICS TOXICITY IS ESSENTIAL TO ASSESS THE BIOSAFETY LEVEL OF GO-AGNPS. 2023 11 3598 14 IMPLICATIONS ON HYPNOTHERAPY: NEUROPLASTICITY, EPIGENETICS AND PAIN. WE PROVIDE A BRIEF REVIEW ABOUT THE SIGNIFICANCE OF HYPNOSIS WITH RESPECT TO APPLICATIONS AND PHYSIOLOGICAL PROCESSES IN HYPNOTHERAPY. OUR REVIEW CONCLUDES THAT HYPNOSIS IS A PROMISING METHOD TO MANAGE ACUTE AND CHRONIC PAIN. IN ADDITION, WE DISCUSS INDICATIONS POINTING TOWARD THE VIEW THAT HYPNOSIS CAN INDUCE CHANGES IN NEUROPLASTICITY POSSIBLY INVOLVING EPIGENETIC MECHANISMS. 2021 12 5500 25 REVISITING MIGRAINE: THE EVOLVING PATHOPHYSIOLOGY AND THE EXPANDING MANAGEMENT ARMAMENTARIUM. MIGRAINE AFFECTS ABOUT ONE BILLION PEOPLE WORLDWIDE YEARLY AND IS ONE OF THE MOST COMMON NEUROLOGIC ILLNESSES, WITH A HIGH PREVALENCE AND MORBIDITY, PARTICULARLY AMONG YOUNG ADULTS AND FEMALES. MIGRAINE IS ASSOCIATED WITH MANY COMORBIDITIES, INCLUDING STRESS, SLEEP DIFFICULTIES, AND SUICIDAL IDEATION. MIGRAINE, DESPITE ITS WIDESPREAD OCCURRENCE, IS UNDERDIAGNOSED AND UNDERTREATED. BECAUSE OF THE COMPLICATED AND PRIMARILY UNKNOWN MECHANISMS OF MIGRAINE FORMATION, SEVERAL SOCIAL AND BIOLOGICAL RISK FACTORS, SUCH AS HORMONE IMBALANCES, GENETIC AND EPIGENETIC IMPACTS, AND CARDIOVASCULAR, NEUROLOGICAL, AND AUTOIMMUNE ILLNESSES, HAVE BEEN PROPOSED. THROUGH THE MID-20TH CENTURY DIVERSION OF THE NOW-DEFUNCT VASCULAR THEORY, THE PATHOPHYSIOLOGY OF MIGRAINE HAS DEVELOPED FROM A HISTORICAL STUDY OF THE "HUMOURS" TO A DISTINCT ENTITY AS A NEUROLOGICAL DISORDER. THE RANGE OF THERAPEUTIC TARGETS HAS BROADENED SIGNIFICANTLY, INCREASING THE NUMBER OF SPECIALIZED CLINICAL TRIALS. UNDERSTANDING THE BIOLOGY OF MIGRAINE THROUGH CAREFUL RESEARCH HAS RESULTED IN THE IDENTIFICATION OF MAJOR THERAPEUTIC CLASSES: (I) TRIPTANS, SEROTONIN 5-HT1B/1D RECEPTOR AGONISTS, (II) GEPANTS, CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR ANTAGONISTS, (III) DITANS, 5-HT1F RECEPTOR AGONISTS, (IV) CGRP MONOCLONAL ANTIBODIES, AND (V) GLURANTS, MGLU5 MODULATORS, WITH FURTHER TARGETS BEING EXPLORED. THIS REVIEW PROVIDES A COMPREHENSIVE OVERVIEW OF THE MOST RECENT LITERATURE ON EPIDEMIOLOGY AND RISK FACTORS AND EXPOSES KNOWLEDGE GAPS. 2023 13 623 22 BIOINFORMATICS FOR CANCER MANAGEMENT IN THE POST-GENOME ERA. HUMAN CANCER IS CAUSED BY MULTIPLE FACTORS, SUCH AS GENETIC PREDISPOSITION, CHRONIC PERSISTENT INFLAMMATION, ENVIRONMENTAL FACTORS, LIFE STYLE, AND AGING. DYSREGULATED PROLIFERATION, DYSREGULATED ADHESION, RESISTANCE TO APOPTOSIS, RESISTANCE TO SENESCENCE, AND RESISTANCE TO ANTI-CANCER DRUGS ARE FEATURES OF CANCER CELLS. ACCUMULATION OF MULTIPLE EPIGENETIC CHANGES AND GENETIC ALTERATIONS OF CANCER-ASSOCIATED GENES DURING MULTI-STAGE CARCINOGENESIS RESULTS IN MORE MALIGNANT PHENOTYPES. POST-GENOME SCIENCE IS CHARACTERIZED BY OMICS DATA RELATED TO GENOME, TRANSCRIPTOME, PROTEOME, METABOLOME, INTERACTOME, AND EPIGENOME AS WELL AS BY HIGH-THROUGHPUT TECHNOLOGY, SUCH AS WHOLE-GENOME TILING OLIGONUCLEOTIDE ARRAY, ARRAY CGH WITH 32,433 OVERLAPPING BAC CLONES, TRANSCRIPTOME MICROARRAY, MASS SPECTROMETRY, TISSUE-BASED EXPRESSION ARRAY, AND CELL-BASED TRANSFECTION ARRAY. BENCHTOP ONCOLOGY SUPPLIES DESKTOP ONCOLOGY WITH LARGE AMOUNTS OF OMICS DATA PRODUCED BY HIGH-THROUGHPUT TECHNOLOGY. DESKTOP ONCOLOGY ESTABLISHES KNOWLEDGE ON CANCER-RELATED BIOMARKERS, SUCH AS PREDISPOSITION MARKERS, DIAGNOSTIC MARKERS, PROGNOSTIC MARKERS, AND THERAPEUTIC MARKERS, BY USING BIOINFORMATICS AND HUMAN INTELLIGENCE OF EXPERTS FOR DATA MINING AND TEXT MINING. BEDSIDE ONCOLOGY APPLIES THE KNOWLEDGE ESTABLISHED BY DESKTOP ONCOLOGY TO DETERMINE THERAPEUTICS FOR CANCER PATIENTS. ANTIBODY DRUGS (TRASTUZUMAB/HERCEPTIN, CETUXIMAB/ERBITUX, BEVACIZUMAB/AVASTIN, ET CETERA), SMALL MOLECULE INHIBITORS FOR TYROSINE KINASES (GEFITINIB/IRESSA, ERLOTINIB/TARCEVA, IMATINIB/GLEEVEC, ET CETERA), CONVENTIONAL CYTOTOXIC DRUGS, AND ANTI-HORMONAL DRUGS ARE USED FOR CANCER CHEMOTHERAPY. BIOMARKER MONITORING CONTRIBUTES TO THERAPEUTIC OPTIONAL CHOICE AND DRUG DOSAGE DETERMINATION FOR CANCER PATIENTS. KNOWLEDGE ON BIOMARKERS IS FEEDFORWARDED FROM DESKTOP TO BEDSIDE IN THE TRANSLATIONAL RESEARCH, AND THEN BIOMARKER MONITORING IS FEEDBACKED FROM BEDSIDE TO DESKTOP IN THE REVERSE TRANSLATIONAL RESEARCH. DESKTOP ONCOLOGY IS INDISPENSABLE FOR CANCER RESEARCH IN THE POST-GENOME ERA. COMBINATION OF GENETIC SCREENING FOR CANCER PREDISPOSITION IN THE GENERAL POPULATION AND PRECISE SELECTION OF THERAPEUTIC OPTIONS DURING CANCER MANAGEMENT COULD CONTRIBUTE TO THE REALIZATION OF PERSONALIZED PREVENTION AND TO DRAMATICALLY IMPROVE THE PROGNOSIS OF CANCER PATIENTS IN THE FUTURE. 2006 14 5501 24 REWRITING THE EPIGENETIC CODE FOR TUMOR RESENSITIZATION: A REVIEW. IN CANCER CHEMOTHERAPY, ONE AXIOM, WHICH HAS PRACTICALLY SOLIDIFIED INTO DOGMA, IS THAT ACQUIRED RESISTANCE TO ANTITUMOR AGENTS OR REGIMENS, NEARLY INEVITABLE IN ALL PATIENTS WITH METASTATIC DISEASE, REMAINS UNALTERABLE AND IRREVERSIBLE, RENDERING THERAPEUTIC RECHALLENGE FUTILE. HOWEVER, THE INTRODUCTION OF EPIGENETIC THERAPIES, INCLUDING HISTONE DEACETYLASE INHIBITORS (HDACIS) AND DNA METHYLTRANSFERASE INHIBITORS (DNMTIS), PROVIDES ONCOLOGISTS, LIKE COMPUTER PROGRAMMERS, WITH NEW TECHNIQUES TO "OVERWRITE" THE MODIFIABLE SOFTWARE PATTERN OF GENE EXPRESSION IN TUMORS AND CHALLENGE THE "ONE AND DONE" TREATMENT PRESCRIPTION. TAKING THE EPIGENETIC CODE-AS-SOFTWARE ANALOGY A STEP FURTHER, IF CHEMORESISTANCE IS THE PRODUCT OF MULTIPLE NONGENETIC ALTERATIONS, WHICH DEVELOP AND ACCUMULATE OVER TIME IN RESPONSE TO TREATMENT, THEN THE POSSIBILITY TO HACK OR TWEAK THE OPERATING SYSTEM AND FALL BACK ON A "SYSTEM RESTORE" OR "UNDO" FEATURE, LIKE THE ARROW ICON IN THE WINDOWS XP TOOLBAR, RECONFIGURING THE TUMOR TO ITS BASELINE NONRESISTANT STATE, HOLDS TREMENDOUS PROMISE FOR TURNING ADVANCED, METASTATIC CANCER FROM A FATAL DISEASE INTO A CHRONIC, LIVABLE CONDITION. THIS REVIEW AIMS 1) TO EXPLORE THE POTENTIAL MECHANISMS BY WHICH A GROUP OF SMALL MOLECULE AGENTS INCLUDING HDACIS (ENTINOSTAT AND VORINOSTAT), DNMTIS (DECITABINE AND 5-AZACYTIDINE), AND REDOX MODULATORS (RRX-001) MAY REPROGRAM THE TUMOR MICROENVIRONMENT FROM A REFRACTORY TO A NONREFRACTORY STATE, 2) HIGHLIGHT SOME RECENT FINDINGS, AND 3) DISCUSS WHETHER THE CURRENT "ONCE BURNED FOREVER SPURNED" PARADIGM IN THE TREATMENT OF METASTATIC DISEASE SHOULD BE REVISED TO PROMOTE ACTIVE RESENSITIZATION ATTEMPTS WITH FORMERLY FAILED CHEMOTHERAPIES. 2014 15 4757 30 NOVEL TREATMENT OPPORTUNITIES FOR SULFUR MUSTARD-RELATED CANCERS: GENETIC AND EPIGENETIC PERSPECTIVES. SULFUR MUSTARD (SM), ALSO KNOWN AS MUSTARD GAS, IS A CHEMICAL WEAPON WHICH BY NOW HAS BEEN USED IN MANY WARS. THE MOST CONCERNING SM TOXIC EFFECT IS PROBABLE CARCINOGENICITY. IN THIS STUDY, THE GENETIC AND EPIGENETIC MECHANISMS OF SM CARCINOGENICITY, BY FOCUSING ON TREATMENT OF SM-ASSOCIATED MALIGNANCIES, PARTICULARLY GENE THERAPEUTICS, CANCER VACCINES, AND EPIGENETIC MEDICATIONS, HAVE BEEN CRITICIZED. THE REQUIRED DATA WERE COLLECTED THROUGH AN ORGANIZED SEARCH ON VALID SCIENTIFIC DATABASES. FOR SM CARCINOGENICITY DUE TO ACUTE OR CHRONIC EXPOSURE, THE ENTIRE ORIGINAL AND REVIEW ARTICLES WERE EVALUATED. IN ADDITION, STUDIES ON THE THERAPEUTIC EFFECTS OF AVAILABLE GENETIC AND EPIGENETIC MEDICATIONS WERE INCLUDED. CURRENTLY, FOUR GENE THERAPEUTICS, TWO CANCER VACCINES WITH GENETIC BASES, AND SEVEN EPIGENETIC MEDICATIONS ARE AVAILABLE FOR CANCER TREATMENT. GENETIC AND EPIGENETIC CANCER TREATMENTS INCLUDING GENDICINE, IMLYGIC, PROVENGE, CIMAVAX-EGF, AZACITIDINE, VORINOSTAT, ROMIDEPSIN, AND BELINOSTAT WILL YIELD OUTSTANDING BENEFITS FOR SM-EXPOSED PATIENTS WHO SUFFER FROM CANCER. 2017 16 2729 22 EXPLORING EPIGENETIC DRUGS AS POTENTIAL INHIBITORS OF SARS-COV-2 MAIN PROTEASE: A DOCKING AND MD SIMULATION STUDY. THE COVID-19 PANDEMIC HAS CAUSED HAVOC AROUND THE GLOBE SINCE 2019 AND IS CONSIDERED THE LARGEST GLOBAL EPIDEMIC OF THE TWENTIETH CENTURY. ALTHOUGH THE FIRST ANTIVIRAL DRUG, REMDESIVIR, WAS INITIALLY INTRODUCED AGAINST COVID?19, VIRTUALLY NO TANGIBLE THERAPEUTIC DRUGS EXIST TO TREAT SARS-COV-2 INFECTION. FDA-APPROVED PAXLOVID (NIRMATRELVIR SUPPLEMENTED BY RITONAVIR) WAS RECENTLY ANNOUNCED AS A PROMISING DRUG AGAINST THE SARS-COV-2 MAJOR PROTEASE (M(PRO)). HERE WE REPORT FOR THE FIRST TIME THE REMARKABLE INHIBITORY POTENTIALS OF LEAD EPIGENETIC-TARGETING DRUGS (EPI-DRUGS) AGAINST SARS-COV-2 M(PRO). EPI-DRUGS ARE PROMISING COMPOUNDS TO BE USED IN COMBINATION WITH CANCER CHEMOTHERAPEUTICS TO REGULATE GENE EXPRESSION. THE SEARCH FOR ALL KNOWN EPI-DRUGS FOR THE SPECIFIC INHIBITION OF SARS-COV-2 M(PRO) WAS PERFORMED FOR THE FIRST TIME BY CONSENSUS (THREE HIGH-ORDER PROGRAM) MOLECULAR DOCKING STUDIES AND END-STATE FREE ENERGY CALCULATIONS. SEVERAL EPI-DRUGS WERE IDENTIFIED WITH HIGHLY COMPARABLE BINDING AFFINITY TO SARS-COV-2 M(PRO) COMPARED TO NIRMATRELVIR. IN PARTICULAR, POTENT HISTONE METHYLTRANSFERASE INHIBITOR EPZ005687 AND DNA METHYLTRANSFERASE INHIBITOR GUADECITABINE WERE PROMINENT AS THE MOST PROMISING EPI-DRUG INHIBITORS FOR SARS-COV-2 M(PRO). LONG MOLECULAR DYNAMICS (MD) SIMULATIONS (200 NS EACH) AND CORRESPONDING MM-GBSA CALCULATIONS CONFIRMED THE STABILITY OF THE EPZ005687-M(PRO) COMPLEX WITH MM-GBSA BINDING FREE ENERGY (DELTAG(BIND)) -48.2 KCAL/MOL (EPZ005687) COMPARED TO NIRMATRELVIR (-44.7 KCAL/MOL). TAKEN TOGETHER, THE ANTIVIRAL ACTIVITIES OF THE HIGHLIGHTED EPI-DRUGS ARE REPORTED BEYOND WIDESPREAD USE IN COMBINATION WITH ANTI-CANCER AGENTS. THE CURRENT FINDINGS THEREFORE HIGHLIGHT AS YET UNEXPLORED ANTIVIRAL POTENTIAL OF EPI-DRUGS SUITABLE FOR USE IN PATIENTS STRUGGLING WITH CHRONIC IMMUNOSUPPRESSIVE DISORDERS.COMMUNICATED BY RAMASWAMY H. SARMA. 2023 17 1101 16 COMBINATION THERAPY USING LHRH AND SOMATOSTATIN ANALOGUES PLUS DEXAMETHASONE IN ANDROGEN ABLATION REFRACTORY PROSTATE CANCER PATIENTS WITH BONE INVOLVEMENT: A BENCH TO BEDSIDE APPROACH. THE DEVELOPMENT OF RESISTANCE TO ANTICANCER THERAPIES IS A MAJOR HURDLE IN PREVENTING LONG-LASTING CLINICAL RESPONSES TO CONVENTIONAL THERAPIES IN HORMONE-REFRACTORY PROSTATE CANCER. HEREIN, THE MOLECULAR EVIDENCE DOCUMENTING THAT BONE METASTASIS MICROENVIRONMENT SURVIVAL FACTORS (MAINLY THE PARACRINE GROWTH HORMONE-INDEPENDENT, UROKINASE-TYPE PLASMINOGEN ACTIVATOR-MEDIATED INCREASE OF IGF-1 AND THE ENDOCRINE PRODUCTION OF GROWTH HORMONE-DEPENDENT IGF-1, MAINLY LIVER-DERIVED IGF-1 PRODUCTION) PRODUCE AN EPIGENETIC FORM OF PROSTATE CANCER CELLS THAT ARE RESISTANT TO PROAPOPTOTIC THERAPIES IS REVIEWED. CONSEQUENTLY, THE AUTHORS PRESENT THE CONCEPTUAL FRAMEWORK OF A NOVEL ANTIBONE MICROENVIRONMENT SURVIVAL FACTOR, MAINLY AN ANTI-IGF-1 HORMONAL MANIPULATION FOR ANDROGEN ABLATION REFRACTORY PROSTATE CANCER (A COMBINATION OF CONVENTIONAL ANDROGEN ABLATION THERAPY [LUTEINISING HORMONE-RELEASING HORMONE AGONIST-A OR ORCHIECTOMY]) WITH DEXAMETHASONE PLUS SOMATOSTATIN ANALOGUE, WHICH YIELDED DURABLE OBJECTIVE RESPONSES AND MAJOR IMPROVEMENT OF BONE PAIN AND PERFORMANCE STATUS IN STAGE D3 PROSTATE CANCER PATIENTS. 2006 18 4990 21 PD-1-CIS IL-2R AGONISM YIELDS BETTER EFFECTORS FROM STEM-LIKE CD8(+) T CELLS. EXPANSION AND DIFFERENTIATION OF ANTIGEN-EXPERIENCED PD-1(+)TCF-1(+) STEM-LIKE CD8(+) T CELLS INTO EFFECTOR CELLS IS CRITICAL FOR THE SUCCESS OF IMMUNOTHERAPIES BASED ON PD-1 BLOCKADE(1-4). HASHIMOTO ET AL. HAVE SHOWN THAT, IN CHRONIC INFECTIONS, ADMINISTRATION OF THE CYTOKINE INTERLEUKIN (IL)-2 TRIGGERS AN ALTERNATIVE DIFFERENTIATION PATH OF STEM-LIKE T CELLS TOWARDS A DISTINCT POPULATION OF 'BETTER EFFECTOR' CD8(+) T CELLS SIMILAR TO THOSE GENERATED IN AN ACUTE INFECTION(5). IL-2 BINDING TO THE IL-2 RECEPTOR ALPHA-CHAIN (CD25) WAS ESSENTIAL IN TRIGGERING THIS ALTERNATIVE DIFFERENTIATION PATH AND EXPANDING BETTER EFFECTORS WITH DISTINCT TRANSCRIPTIONAL AND EPIGENETIC PROFILES. HOWEVER, CONSTITUTIVE EXPRESSION OF CD25 ON REGULATORY T CELLS AND SOME ENDOTHELIAL CELLS ALSO CONTRIBUTES TO UNWANTED SYSTEMIC EFFECTS FROM IL-2 THERAPY. THEREFORE, ENGINEERED IL-2 RECEPTOR BETA- AND GAMMA-CHAIN (IL-2RBETAGAMMA)-BIASED AGONISTS ARE CURRENTLY BEING DEVELOPED(6-10). HERE WE SHOW THAT IL-2RBETAGAMMA-BIASED AGONISTS ARE UNABLE TO PREFERENTIALLY EXPAND BETTER EFFECTOR T CELLS IN CANCER MODELS AND DESCRIBE PD1-IL2V, A NEW IMMUNOCYTOKINE THAT OVERCOMES THE NEED FOR CD25 BINDING BY DOCKING IN CIS TO PD-1. CIS BINDING OF PD1-IL2V TO PD-1 AND IL-2RBETAGAMMA ON THE SAME CELL RECOVERS THE ABILITY TO DIFFERENTIATE STEM-LIKE CD8(+) T CELLS INTO BETTER EFFECTORS IN THE ABSENCE OF CD25 BINDING IN BOTH CHRONIC INFECTION AND CANCER MODELS AND PROVIDES SUPERIOR EFFICACY. BY CONTRAST, PD-1- OR PD-L1-BLOCKING ANTIBODIES ALONE, OR THEIR COMBINATION WITH CLINICALLY RELEVANT DOSES OF NON-PD-1-TARGETED IL2V, CANNOT EXPAND THIS UNIQUE SUBSET OF BETTER EFFECTOR T CELLS AND INSTEAD LEAD TO THE ACCUMULATION OF TERMINALLY DIFFERENTIATED, EXHAUSTED T CELLS. THESE FINDINGS PROVIDE THE BASIS FOR THE DEVELOPMENT OF A NEW GENERATION OF PD-1 CIS-TARGETED IL-2R AGONISTS WITH ENHANCED THERAPEUTIC POTENTIAL FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIONS. 2022 19 5392 27 REDOXISOME AND DIABETIC RETINOPATHY: PATHOPHYSIOLOGY AND THERAPEUTIC INTERVENTIONS. DIABETIC RETINOPATHY (DR) IS A CHRONIC MICROVASCULAR COMPLICATION OF DIABETES MELLITUS (DM). IT IS A WORLDWIDE GROWING EPIDEMIC DISEASE CONSIDERED TO BE THE LEADING CAUSE OF VISION-LOSS AND BLINDNESS IN PEOPLE WITH DM. REDOX REACTIONS OCCURRING AT THE EXTRA- AND INTRACELLULAR LEVELS ARE ESSENTIAL FOR THE MAINTENANCE OF CELLULAR HOMEOSTASIS. DYSREGULATION OF REDOX HOMEOSTASIS ARE IMPLICATED IN THE ONSET AND DEVELOPMENT OF DR. THIOREDOXIN1 (TRX1) AND THIOREDOXIN2 (TRX2) ARE CYTOPLASMIC AND MITOCHONDRIALLY LOCALIZED ANTIOXIDANT PROTEINS UBIQUITOUSLY EXPRESSED IN VARIOUS CELLS AND CONTROL CELLULAR REACTIVE OXYGEN SPECIES (ROS) BY REDUCING THE DISULFIDES INTO THIOL GROUPS. THIOREDOXIN-INTERACTING PROTEIN (TXNIP) BINDS TO TRX SYSTEM AND INHIBITS THE ACTIVE REDUCED FORM OF TRX THROUGH DISULFIDE EXCHANGE REACTION. RECENT STUDIES INDICATE THE ASSOCIATION OF TRX/TXNIP WITH REDOX SIGNAL TRANSDUCTION PATHWAYS INCLUDING ACTIVATION OF NOD-LIKE RECEPTOR PYRIN DOMAIN CONTAINING PROTEIN-3 (NLRP3) INFLAMMASOME, APOPTOSIS, AUTOPHAGY/MITOPHAGY, EPIGENETIC MODIFICATIONS IN A REDOX-DEPENDENT MANNER. THUS, IT IS IMPORTANT TO GAIN A MORE IN-DEPTH UNDERSTANDING ABOUT THE CELLULAR AND MOLECULAR MECHANISMS THAT LINKS REDOXISOME AND ER/MITOCHONDRIAL DYSFUNCTION TO DRIVE THE PROGRESSION OF DR. THE PURPOSE OF THIS REVIEW IS TO PROVIDE A MECHANISTIC UNDERSTANDING OF THE COMPLEX MOLECULAR MECHANISMS AND PATHOPHYSIOLOGICAL ROLES ASSOCIATED WITH REDOXISOME, THE TRX/TXNIP REDOX SIGNALING COMPLEX UNDER OXIDATIVE STRESS IN THE DEVELOPMENT OF DR. ALSO, THE MOLECULAR TARGETS OF FDA APPROVED DRUGS AND CLINICAL TRIALS IN ADDITION TO EFFECTIVE ANTIOXIDANT STRATEGIES FOR THE TREATMENT OF DIABETIC RETINOPATHY ARE REVIEWED. 2022 20 486 25 ASENAPINE TRANSDERMAL PATCH FOR THE MANAGEMENT OF SCHIZOPHRENIA. PURPOSE OF REVIEW: THIS IS A COMPREHENSIVE REVIEW OF THE LITERATURE REGARDING THE USE OF ASENAPINE FOR THE TREATMENT OF SCHIZOPHRENIA (SZ) IN ADULTS. IT COVERS AN INTRODUCTION, EPIDEMIOLOGY, RISK FACTORS, PATHOPHYSIOLOGY, AND CURRENT TREATMENT MODALITIES REGARDING SZ, PROVIDES A BACKGROUND ON THE MECHANISM OF ACTION OF ASENAPINE, AND THEN REVIEWS THE EXISTING EVIDENCE FOR USE OF ASENAPINE IN BOTH ITS SUBLINGUAL AND TRANSDERMAL FORMULATION IN THE TREATMENT OF SZ. RECENT FINDINGS: SZ IS A COMPLEX AND MULTIFACTORIAL MENTAL DISORDER WHICH IS THOUGHT TO COMBINE SEVERAL GENETIC, EPIGENETIC, AND ENVIRONMENTAL FACTORS CAUSING ABNORMALITIES IN THE DOPAMINERGIC SYSTEM. SYMPTOMS ARE CATEGORIZED IN DELUSIONS, HALLUCINATIONS, DISORGANIZATION, AND NEGATIVE PRESENTATIONS LIKE AFFECTIVE FLATTENING AND APATHY. CURRENT TREATMENT FOCUSES ON ANTIPSYCHOTIC MEDICATIONS BY MEANS OF ORAL ADMINISTRATION OR LONG-ACTING INJECTION. ASENAPINE IS A SECOND-GENERATION ANTIPSYCHOTIC WITH 5HT-2A ANTAGONIST AND 5HT-1A/1B PARTIAL AGONIST PROPERTIES, WHICH PROVIDES A FAVORABLE PROFILE IN TARGETING SCHIZOPHRENIC SYMPTOMS, WHILE REDUCING MOTOR SIDE EFFECTS AND IMPROVING MOOD AND COGNITION. ASENAPINE IN ITS SUBLINGUAL FORMULATION WAS FDA APPROVED FOR TREATMENT OF SZ AND BIPOLAR I DISORDER IN ADULTS IN AUGUST OF 2009 AND HAS BEEN PROVEN TO BE BOTH EFFECTIVE AND SAFE. TRANSDERMAL PATCH OF ASENAPINE (SECUADO) WAS FDA APPROVED IN OCTOBER OF 2019, THE FIRST AND ONLY FDA APPROVED PATCH FOR SZ IN ADULTS, WHICH OFFERS ANOTHER STRATEGY FOR TREATMENT TO IMPROVE COMPLIANCE AND EASE OF ADMINISTRATION. SUMMARY: SZ IS A CHRONIC AND DEBILITATING DISEASE WHICH IS STILL NOT WELL UNDERSTOOD AND COMES AT GREAT COST WITH REGARDS TO THE QUALITY OF LIFE FOR PATIENTS. MEDICATION SIDE-EFFECTS AND COMPLIANCE ARE ENORMOUS ISSUES WHICH TAKE A TOLL ON HEALTH CARE SYSTEMS IN INDUSTRIALIZED NATIONS AND KEEP PATIENTS FROM ACHIEVING STABILITY WITH THEIR DISEASE. TRANSDERMAL ASENAPINE IS A NEW FIRST-IN-CLASS DOSAGE FORM AND PROVIDES A NOVEL MODALITY OF ADMINISTRATION. IT HAS BEEN SHOWN TO BE EFFECTIVE IN REDUCING POSITIVE, AS WELL AS NEGATIVE SYMPTOMS, WHILE STILL MAINTAINING A FAVORABLE SIDE-EFFECT PROFILE. 2020